PATENT Attorney Docket No. 25734X

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

POPP

Serial No.:

10/791,839

Filing Date:

March 4, 2004

For:

ANTIMICROBIAL TOPICAL COMPOSITIONS FOR TREATMENT

OF ROSACEA

## TRANSMITTAL LETTER

Commissioner for Patents Washington, D.C. 20231

Sir:

Submitted herewith for filing in the U.S. Patent and

Trademark Office is the following:

- 1) Transmittal Letter;
- Information Disclosure Statement; 2)
- 3) PTO-Form 1449; and
- 4) One (1) Reference Cited.

The Commissioner is specifically authorized to charge any required fee deficiency under 37 CFR §§ 1.16 or 1.17, or credit any overpayment, to Deposit Account No. 14-0112 in connection with this matter.

Respectfully submitted,

NATH & ASSOCIATES PLLC

NATH & ASSOCTATES

1030 Fifteenth Street, N.W.

Sixth Floor

Washington, D.C. 20005

Tel: (202) 775-8383

Fax: (202) 775-8396

GMN: JBG: \ids-tl.doc

Gary M. Nath

Red. No. 26,965

Joshua B. Goldberg

Reg. No. 44,126

Customer No. 20529



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

POPP

Serial No.:

10/791,839

Filing Date:

March 4, 2004

For:

ANTIMICROBIAL TOPICAL COMPOSITIONS FOR TREATMENT OF

ROSACEA

## INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents Washington, D.C. 20231

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. §1.97-1.98. Please note the following particulars:

[NOTE: One only of items a, b, c, and d must be checked.]
[X] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

- [ ] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311.
  - The enclosed statement is accompanied by [check one]:
  - [] i. a certification in part (e) below as specified in 37 C.F.R. § 1.97(e), or
  - [ ] ii. a check in the amount required by 37 C.F.R. § 1.17(p).
- [ ] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311, but before payment of the issue fee.
  - [ ] Certification report(e) below; and
  - [] a check in the amount as required by § 1.17(p).
- [ ] d. The enclosed statement is being filed pursuant to 37 C.F.R. § 1.97(i), for placement in the file.

- [ ] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]
  - [ ] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

- [ ] Appropriate certification is attached.
- [ X ] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.
- [ X ] g. Copies of the non-U.S. patent documents are attached herewith with a completed Form PTO-1449.

and

[X] Copies of the documents are not attached as allowed under CFR § 1.98(d)(1)(2). The earlier application is identified as:
U.S. Patent Application Serial No. 10/698,431 filed on November 3, 2003

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Date: N.W., 6<sup>th</sup> Floor

Washington, D.C. 20005-1503

Tel. (202) 775-8383 Fax. (202) 775-8396

GMN:JBG (IDS.doc)

NATH & ASSOCIATES PLLC

Gary M Nath

Registration No. 26,969

Respectfully submitted,

Joshua B. Goldberg

Registration No. 44,126

Customer No. 20529

Examiner

Atty. Docket 25734X

Serial No. 10/791,839

Date Considered

MAY 2 5	ابير 2004					10/ / 2	71,033
MAY 2 5	or o	FORM PTO-1449		Applicant	POPP		
FORM PTO-1449  FORM PTO-1449  INFORMATION DISCLOSURE CITATION				Filing Date Group Art Unit			
			U.S. PAT	ENT DOCUMENTS			<del></del>
Examiner Initial		Document Number	Issue Date	Name	Class	Sub- Class	Filing Date
	AA	3,867,522	02/18/75	Kligman			10/11/73
	AB	4,185,106	01/22/80	Dittmar et al.			08/15/75
<del></del>	AC	4,711,775	12/08/87				12/04/84
-·	AD	4,736,756	04/12/88	Grollier et al.			09/18/85
	AE	4,762,847	08/09/88	Edwards et al.			10/02/86
	AF	5,174,475	12/29/92	Day et al.			03/26/91
	AG	5,470,880	11/28/95	Yu et al.			01/10/94
	AH	5,487,884	01/30/96	Bissett et al.			07/01/93
	AI	5,654,013	08/05/97	Taylor et al.			03/13/95
	AJ	5,665,364	09/09/97	McAtee et al.			07/24/95
· · · · · · · · · · · · · · · · · · ·	AK	5,665,776	09/09/97	Yu et al.			01/22/93
	AL	5,919,438	07/06/99	Saint-Leger			04/15/97
<del></del>	AM	5,939,083	08/17/99	Allec et al.			06/09/97
	AN	5,952,372	09/14/99	McDaniel			09/14/99
<del></del>	AO	5,972,993	10/26/99	Ptchelintsev			03/20/98
	AP	5,998,395	12/07/99	Kligman			09/10/93
	AQ	6,075,017	06/13/00	Dascalu et al.			06/13/00
<del></del>	AR	6,121,254	09/19/00	Saint Leger			09/19/00
	AS	6,136,806	10/24/00	Hittel			11/20/98
	AT	6,174,534	01/16/01	Richard et al.			02/03/99
	AU	6,207,694	03/27/01	Murad			07/27/98
	AV	6,231,875	05/15/01	Sun et al.			03/09/99
	AW	6,284,234	09/04/01	Niemiec et al.			07/23/99
	AX	6,335,023	01/01/02	Yu et al.			01/19/00
	AY	6,352,724	03/05/02	Taylor et al.			03/11/96
	AZ	6,375,939	04/23/02	Dubief et al.			06/23/00
	AAA	6,383,523	05/07/02	Murad			06/12/01
	AAB	6,387,383	05/14/02	Dow et al.			08/03/00
	AAC	6,419,913	07/16/02	Niemiec et al.			07/26/01
	AAD	6,440,994	08/27/02	Sanders, Jr.			03/29/01
	AAE	6,455,551	09/24/02	Bohn et al.			06/03/98
	AAF	6,469,033	10/22/02	Bohn et al.			08/20/98
	AAG	6,495,498	12/17/02	Niemiec et al.			05/27/99

Atty. Docket 25734X Serial No. 10/791,839

Applicant

POPP

FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Filing Date March 4, 2004

Group Art Unit

	INFOR	TATION DISCLOSURE	CITATION	March 4, 20	04	n	/a
	_		U.S. PAT	ENT DOCUMENTS			
Examiner Initial		Document Number	Issue Date	Name	Name Class Clas		Filing Date
	BA	6,515,007	02/04/03	Murad			08/03/01
	ВВ	6,517,847	02/11/03	Dow et al.			03/08/02
	ВC	6,524,594	02/25/03	Santora et al.			05/26/00
	BD	6,534,069	03/18/03	Asmus et al.			06/08/99
· ··	BE	6,562,360	05/13/03	Scholz et al.			12/10/01
	BF	6,582,711	06/24/03	Asmus et al.			01/09/97
	BG	6,586,472	07/01/03	Perricone  Burnier  Yu et al.  Robinson et al.			09/14/01
	ВН	6,599,512	07/29/03				10/03/97
	BI	2001/0016604	08/23/01				02/01/01
	ВJ	2002/0022040	02/21/02				05/29/01
	BK	2002/0035046	03/21/02	Lukenbach et al.			12/21/00
	BL	2002/0064541	05/30/02	Lapidot et al.			10/23/01
	BM	2002/0168327	11/14/02	Bailey et al.			02/26/02
	BN	2002/0172719	11/21/02	Murad			03/11/02
	во	2003/0007939	01/09/03	Murad			02/20/02
	BP	2003/0069148	04/10/03	Booker et al.		-	09/17/01
	BQ	2003/0108507	06/12/03	Clipson et al.  Kundel  Seitz, Jr. et al.  Fan et al.			10/18/02
	BR	2003/0118655	06/26/03				12/21/01
	BS	2003/0125224	07/03/03				07/10/02
	BT	2003/0133899	07/17/03				12/16/02
	BU	2003/0134759	07/17/03	Geary et al.			11/01/02
	BV	2003/0228340	12/11/03	Gans			04/04/03
			FOREIGN PA	ATENT DOCUMENTS			<del></del>
		Document Number	Date	Country	Class	Sub- Class	Trans- lation
	BW	EP 0,217,635 A1	,217,635 A1 04/08/87 EPO			Yes	
	BX	EP 0,312,234 A1	04/19/89	EPO			Yes
	BY	EP 0,347,199 B1	09/09/92	EPO			Yes
	BZ	EP 0,771,187 B1	10/28/98	EPO			Yes
	BAA	EP 0,928,183 B1	12/05/01	EPO			Yes
	BAB	EP 0,928,193 B1	06/12/02				Yes
	BAC	EP 1,282,390 A1	11/15/01				Yes
	BAD EP 1,312,356 A1 05/2		05/21/03	EPO			Yes
BAE		EP 1,329,212 A1	07/23/03	EPO			Yes
Examiner				Date Considered	i		

			Atty. Docket 25734X	Serial	No. 0/791,839			
FORM PTO	Applicant POPP							
INFORMATION DISC	Filing Date March 4, 2004	Group Art Unit						
FOREIGN PATENT DOCUMENTS								
CA CA 2,285,3	68 Al 10/98/	8	Canada		Yes			
CB CA 2,294,8	04 A1 11/26/	8	Canada		Yes			
CC CA 2,351,9	25 A1 12/27/0	)1	Canada		Yes			
CD CA 2,421,7	87 A1 02/04/0	)3	Canada		Yes			
CE CA 2,426,6	83 A1 05/02/0	)2	Canada		Yes			
CF FR 2,685,8	67 A1 07/09/9	3	France		Yes			
CG FR 2,694,6	94 A1 02/18/9	4	France		Yes			
Schoe	OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Schoefer, "Therapy for seborrheic eczema in HIV infection", Forschung und Praxis, Jan. 1990, 98F, p. 3.							
CI Versi	Schneider, "Sun, Sweating and a Fungus Can Give Rise to Pityriasis versicolor", Aerzte-Zeitung, May 1996, 15(94).							
CJ pp. 9	Hanel et al., "Treatment of seborrheic eczema using an antimycotic with antiphlogistic properties", Mycoses, Aug. 1991, 34 Suppl. 1, pp. 91-93.							
1 777 1 1219 511 5	Cullen et al., "Treatment of Tinea Versicolor with a New Antifungal Agent, Ciclopirox Olamine Cream 1%", Clin. Ther., 1985, 7(5), pp. 574-583.							
CL pp. 3	Jue et al., "Ciclopirox Olamine 1% Cream A Preliminary Review of its Antimicrobial Activity and Therapeutic Use", Drugs, 1985, 29, pp. 330-341.							
	Davies et al., "Comparative efficacy of shampoos containing coal tar (4.0% w/w; Tarmed"), coal tar (4.0% w/w) plus ciclopirox olamine (1.0% w/w; Tarmed <sup>TM</sup> AF) and ketoconazole (2.0% w/w; Nizoral®) for the treatment of dandruff/seborrheic dermatitis", J. Derm. Treatment, 1999, 10, pp. 177-183.							
CN			277 100.					
со								
СР								
CQ								
Examiner			Date Considered					

. . ٠.